Top

Published in:

01-09-2017 | Editorial

Pathology of idiopathic non-cirrhotic portal hypertension

Author: Masayoshi Kage

Published in: Hepatology International | Issue 5/2017

Excerpt

Idiopathic non-cirrhotic portal hypertension (INCPH) represents diseases in which splenomegaly, anemia, and portal hypertension occur but no causative disease, such as liver cirrhosis, occlusion of the extrahepatic portal vein/hepatic vein, blood disease, parasitic disease, granulomatous liver disease, or congenital hepatic fibrosis, can be demonstrated [1, 2]. …

Schouten JN, Garcia-Pagan JC, Valla DC, Janseen HL. Idiopathic portal hypertension. Hepatology. 2011;54:1071–1081CrossRefPubMed

Khanna R, Sarin SK. Non-cirrhotic portal hypertension—diagnosis and management. J Hepatol. 2014;60:421–441CrossRefPubMed

Hidaka H, Ohbu M, Kokubu S, Shibuya A, Saigenji K, Okayasu I. Hepatocellular carcinoma associated with idiopathic portal hypertension: review of large nodules in seven non-cirrhotic portal hypertensive livers. J Gastroenterol Hepatol. 2005;20:493–495CrossRefPubMed

Sato Y, Sawada S, Kozaka K, Harada K, Sasaki M, Matsui O, Nakanuma Y. Significance of enhanced expression of nitric oxide syntheses in splenic sinus lining cells in altered portal hemodynamics of idiopathic portal hypertension. Dig Dis Sci. 2007;52:1987–1989CrossRefPubMed

Nakanuma Y, Sato Y, Kiktao A. Pathology and pathogenesis of portal venopathy in idiopathic portal hypertension: hints from systemic sclerosis. Hepatol Res. 2009;39:1023–1031. doi:10.1111/j.1872-034X.2009.00555.x CrossRefPubMed

Kitao A, Sato Y, Sawada-Kitamura S, Harada K, Sasaki M, Morikawa H, Shiomi S, Honda M, Matsui O, Nakanuma Y. Endothelial to mesenchymal transition via transforming growth factor-beta1/Smad activation is associated with portal venous stenosis in idiopathic portal hypertension. Am J Pathol. 2009;175:616–626. doi:10.2353/ajpath.2009.081061 CrossRefPubMedPubMedCentral

Verheij J, Schouten JNL, Komuta M, et al. Histological features in western patients with idiopathic non-cirrhotic portal hypertension. Histopathology. 2013;62:1083–1091CrossRefPubMed

Nayak NC, Jain D, Saigal S, Soin AS. Non-cirrhotic portal fibrosis: one disease with many names? An analysis from morphological study of native explant livers with end stage chronic liver disease. J ClinPathol. 2011;64(7):592–598

Lee H, Ainechi S, Singh M, et al. Histological spectrum of idiopathic noncirrhotic portal hypertension in liver biopsies from dialysis patients. Int J SurgPathol. 2015;23:439–446

10.

Wanless IR, Godwin TA, Allen F, Feder A. Nodular regenative hyperplasia of the liver in hematologic disorders: a possible response to obliterative portal venopathy. Medicine (Batimore). 1980;59:367–379CrossRef

11.

Zuo C, Chumbalkar V, Ells PF, Bonville DJ, Lee H. Prevalence of histological features of idiopathic noncirrhotic portal hypertension in general population: a retrospective study of incidental liver biopsies. Hepatol Int. 2017;. doi:10.1007/s12072-017-9801-6 (epub ahead of print) PubMed

12.

Guido Maria, et al. Obliterative portal venopathy without portal hypertension: an underestimated condition. Liver Int. 2016;36:454–460CrossRefPubMed

13.

Cazals-Hatem D, Hillaire S, Rudler M, Plessier A, Paradis V, Condat B, Francoz C, Denninger MH, Durand F, Bedossa P, Valla DC. Obliterative portal venopathy: portal hypertension is not always present at diagnosis. J Hepatol. 2011;54:455–461CrossRefPubMed

14.

Wanless IR, Bernier V, Seger M. Intrahepatic portal sclerosis in patients without history of liver disease: an autopsy study. Am J Pathol. 1982;106:63–70PubMedPubMedCentral

15.

Fukuda K, Kage M, Arakawa M, Nakashima T. Portal vein or hepatic vein? A curious aberrant vasculature in the liver with idiopathic portal hypertension. Acta Pathol Jpn. 1985;5:885–897

16.

Ohbu M, Okudaira M, Watanabe K, Kaneko S, Takai T. Histopathological study of intrahepatic aberrant vessels in cases of noncirrhotic portal hypertension. Hepatology. 1994;20:302–308CrossRefPubMed

17.

Sato Y, Harada K, Sasaki M, Nakanuma Y. Altered intrahepatic microcirculation of idiopathic portal hypertension in relation to glutamine synthetase expression. Hepatol Res. 2015;45:1323–1330CrossRefPubMed

Title: Pathology of idiopathic non-cirrhotic portal hypertension
Author: Masayoshi Kage
Publication date: 01-09-2017
Publisher: Springer India
Published in: Hepatology International / Issue 5/2017
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI: https://doi.org/10.1007/s12072-017-9823-0

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Pathology of idiopathic non-cirrhotic portal hypertension

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 5/2017

A cinnamon-derived procyanidin type A compound inhibits hepatitis C virus cell entry

Ledipasvir/sofosbuvir without ribavirin is effective in the treatment of recurrent hepatitis C virus infection post-liver transplant

Prevalence of histological features of idiopathic noncirrhotic portal hypertension in general population: a retrospective study of incidental liver biopsies

A brief review on prognostic models of primary biliary cholangitis

Liver failure determines the outcome in patients of acute-on-chronic liver failure (ACLF): comparison of APASL ACLF research consortium (AARC) and CLIF-SOFA models

Enhanced efficacy of radiofrequency ablation for hepatocellular carcinoma using a novel vascular disrupting agent, CKD-516

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page